search
Back to results

A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions

Primary Purpose

Depressive Disorder, Major

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
BI 1358894
Placebo matching BI 1358894
Citalopram
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depressive Disorder, Major

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients having a diagnosis of a MDD according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) (single episode or recurrent) with a MADRS total score between ≥ 7 and < 26 at screening.
  • Male or female aged 18 to 45 years, inclusive at screening.
  • Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control.
  • Patients must be, in the opinion of the Investigator, capable of and eligible for completing the fMRI and tasks.
  • Patients must be right-handed.
  • Patients must have acceptable weight as defined by BMI (weight [kg]/height [m]²) range of 18 to 30 kg/m², inclusive at Visit 1.
  • Patients must be a non-smoker or light smoker (≤ 5 cigarettes per day).
  • Patients must have signed the informed consent form prior to the first study-related procedure indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • Further inclusion criteria apply

Exclusion Criteria:

  • Meeting any diagnostic criteria for a major psychiatric disorder (other than MDD), as determined by DSM-V at screening.
  • Has received a prescribed medication (including antidepressants) within 28 days prior to Visit 1 (apart from the contraceptive pill) or having received over the counter medication (including pain killers) within 10 days prior to screening. Participants who have taken prescription medication may still be entered into the study, if, in the opinion of the Investigator, the medication received will not interfere with the study procedures or compromise safety.
  • Patients where it is foreseen (per investigator judgement) that a delay of initiation of standard of care therapy for the depressive disorder to 14 days after day 1 of Visit 2 is medically not justifiable.
  • A history of alcohol or substance dependence or abuse within the last 12 months from Visit 1.
  • Has a current or recent history of clinically significant suicidal ideation within the past 6 months, corresponding to a score of 4 or 5 for ideation on the C-SSRS, or a history of suicidal behavior within the past year, as validated by the C-SSRS at screening or treatment visit.
  • Has a history of, or presents (in the opinion of the Investigator) with, significant neurological or psychiatric conditions (such as stroke, traumatic brain injury, seizures, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, schizophrenia, blackouts requiring hospitalisation).
  • A planned medical treatment within the study period that might interfere with the study procedures.
  • Further exclusion criteria apply

Sites / Locations

  • Charité - Universitätsmedizin Berlin

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

BI 1358894

Citalopram

Placebo matching BI 1358894

Arm Description

Outcomes

Primary Outcome Measures

Mean Blood Oxygenation Level Depend (BOLD) Signal % change in an emotional paradigm, based on the emotional faces from the Warsaw set of Emotional Facial Expression Pictures (WSEFEP)
The primary endpoint was the mean BOLD signal % change in an emotional paradigm, based on the emotional faces from the Warsaw Set of Emotional Facial Expression Pictures (WSEFEP) in the corticolimbic system comprising the following eight brain regions of interest: Amygdala left Amygdala right Dorsolateral prefrontal cortex left Dorsolateral prefrontal cortex right Insula left Insula right Anterior cingulate cortex left Anterior cingulate cortex right

Secondary Outcome Measures

mean BOLD signal % change in an emotional paradigm in the corticolimbic system using the affective pictures of the Open Affective Standardised Image Set (OASIS).
The secondary endpoint was the mean BOLD signal % change in an emotional paradigm (affective picture set - OASIS task) in the corticolimbic system, consisting of eight brain regions: Amygdala left Amygdala right Dorsolateral prefrontal cortex left Dorsolateral prefrontal cortex right Insula left Insula right Anterior cingulate cortex left Anterior cingulate cortex right

Full Information

First Posted
February 25, 2019
Last Updated
November 18, 2021
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT03854578
Brief Title
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
Official Title
A Single Dose, Randomized, Placebo Controlled Phase I Study on the Effects of BI 1358894 on Functional MRI Measurements in an Emotional Processing Paradigm in Patients With Major Depressive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
March 12, 2019 (Actual)
Primary Completion Date
August 27, 2019 (Actual)
Study Completion Date
September 23, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
To assess the effect of a single dose of BI 1358894 compared to placebo on BOLD responses in modulating brain processing of emotional and cognitive stimuli on the amygdala and related brain structure using fMRI in in unmedicated patients with depression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depressive Disorder, Major

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
73 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BI 1358894
Arm Type
Experimental
Arm Title
Citalopram
Arm Type
Experimental
Arm Title
Placebo matching BI 1358894
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BI 1358894
Intervention Description
Film-coated tablet
Intervention Type
Drug
Intervention Name(s)
Placebo matching BI 1358894
Intervention Description
Film-coated tablet
Intervention Type
Drug
Intervention Name(s)
Citalopram
Intervention Description
Film-coated tablet
Primary Outcome Measure Information:
Title
Mean Blood Oxygenation Level Depend (BOLD) Signal % change in an emotional paradigm, based on the emotional faces from the Warsaw set of Emotional Facial Expression Pictures (WSEFEP)
Description
The primary endpoint was the mean BOLD signal % change in an emotional paradigm, based on the emotional faces from the Warsaw Set of Emotional Facial Expression Pictures (WSEFEP) in the corticolimbic system comprising the following eight brain regions of interest: Amygdala left Amygdala right Dorsolateral prefrontal cortex left Dorsolateral prefrontal cortex right Insula left Insula right Anterior cingulate cortex left Anterior cingulate cortex right
Time Frame
Up to 6 hours.
Secondary Outcome Measure Information:
Title
mean BOLD signal % change in an emotional paradigm in the corticolimbic system using the affective pictures of the Open Affective Standardised Image Set (OASIS).
Description
The secondary endpoint was the mean BOLD signal % change in an emotional paradigm (affective picture set - OASIS task) in the corticolimbic system, consisting of eight brain regions: Amygdala left Amygdala right Dorsolateral prefrontal cortex left Dorsolateral prefrontal cortex right Insula left Insula right Anterior cingulate cortex left Anterior cingulate cortex right
Time Frame
Up to 6 hours.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients having a diagnosis of a MDD according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) (single episode or recurrent) with a MADRS total score between ≥ 7 and < 26 at screening. Male or female aged 18 to 45 years, inclusive at screening. Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control. Patients must be, in the opinion of the Investigator, capable of and eligible for completing the fMRI and tasks. Patients must be right-handed. Patients must have acceptable weight as defined by BMI (weight [kg]/height [m]²) range of 18 to 30 kg/m², inclusive at Visit 1. Patients must be a non-smoker or light smoker (≤ 5 cigarettes per day). Patients must have signed the informed consent form prior to the first study-related procedure indicating they understand the purpose of and procedures required for the study and are willing to participate in the study. Further inclusion criteria apply Exclusion Criteria: Meeting any diagnostic criteria for a major psychiatric disorder (other than MDD), as determined by DSM-V at screening. Has received a prescribed medication (including antidepressants) within 28 days prior to Visit 1 (apart from the contraceptive pill) or having received over the counter medication (including pain killers) within 10 days prior to screening. Participants who have taken prescription medication may still be entered into the study, if, in the opinion of the Investigator, the medication received will not interfere with the study procedures or compromise safety. Patients where it is foreseen (per investigator judgement) that a delay of initiation of standard of care therapy for the depressive disorder to 14 days after day 1 of Visit 2 is medically not justifiable. A history of alcohol or substance dependence or abuse within the last 12 months from Visit 1. Has a current or recent history of clinically significant suicidal ideation within the past 6 months, corresponding to a score of 4 or 5 for ideation on the C-SSRS, or a history of suicidal behavior within the past year, as validated by the C-SSRS at screening or treatment visit. Has a history of, or presents (in the opinion of the Investigator) with, significant neurological or psychiatric conditions (such as stroke, traumatic brain injury, seizures, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, schizophrenia, blackouts requiring hospitalisation). A planned medical treatment within the study period that might interfere with the study procedures. Further exclusion criteria apply
Facility Information:
Facility Name
Charité - Universitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
10117
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing
Links:
URL
http://trials.boehringer-ingelheim.com
Description
Related Info

Learn more about this trial

A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions

We'll reach out to this number within 24 hrs